SOPHIA ANTIPOLIS, FRANCE--(Marketwire - March 21, 2012) -
Jerry St. Peter appointed Executive Vice President and General Manager of
NicOx S.A. (NYSE Euronext Paris: COX) today announces the appointment of
St. Peter as Executive Vice President and General Manager of NicOx
U.S. subsidiary of NicOx. Mr. St. Peter has a successful commercial track-
in specialty pharmaceutical companies, with an extensive knowledge
ophthalmology market in the United States. In particular, he
developed the commercial unit of Inspire Pharmaceuticals,
ophthalmology-focused company acquired by Merck & Co. for $430 million
In tight collaboration with NicOx's European headquarters, Mr. St. Peter
responsible for identifying and evaluating North American opportunities
be exploited globally, in order to build NicOx's late-stage
portfolio. Mr. St. Peter will also lead the development of NicOx's
ophthalmology business. He will be part of NicOx's Executive Committee and
report to Michele Garufi, Chairman and CEO.
The appointment of Mr. St. Peter is part of NicOx's strategy to
international late-stage development and commercial ophthalmology company
around therapeutics, diagnostics and devices. NicOx announced today, March
that it had acquired 11.8% of the shares of Altacor, a
ophthalmology company based in the United Kingdom, and entered into an
option agreement to acquire the remaining shares of Altacor, as the first
in achieving this goal. A number of other opportunities are currently
discussion which could lead to additional M&A or in-licensing to
balanced ophthalmology pipeline across the United States and Europe.
Michele Garufi, Chairman and CEO of NicOx, said: "I am very pleased to
Jerry as a permanent member of the NicOx team. Jerry has been working with
as a consultant for the past five months, helping us in the ongoing
of a number of ophthalmology companies and products. Jerry has an
track record in the development of commercial infrastructure and
strong network of Key Opinion Leaders across the United States. He will be
asset in the creation and future expansion of our presence in the United
as we work towards delivering our strategy of building
international ophthalmology Company."
Mr. St. Peter has more than 22 years of executive leadership
involving specialty pharmaceutical strategy planning, marketing, sales,
markets, financial management, business development and M&A
St. Peter joined Inspire in 2003 and held the positions of Senior
President, Ophthalmology Business Unit, Senior Vice President, Sales and
Markets and Vice President of Sales. He was responsible for building
commercial business, where he successfully launched Elestat®
ophthalmic solutions. He also led Inspire's co-promotion partnership
Allergan for Restasis® ophthalmic emulsion.
Prior to joining Inspire, Mr. St. Peter held a number of leadership
for Muro Pharmaceutical, Inc., a private ophthalmic, pulmonary,
allergy specialty pharmaceutical company. He was responsible for the
the commercial function and served on the company's Executive Management
Mr. St. Peter holds a Bachelor of Science in Health Education
University of Massachusetts, Lowell.
Jerry St. Peter commented: "I am delighted to be joining NicOx at this
stage in its development. I believe the Company's decision to focus on
a mid-sized ophthalmology business is both strategic and well timed.
already has some important assets within eye care, including its
agreement with Altacor announced today, the positive phase 2b results with
303259-X as well as promising early-stage nitric oxide-donating
United States is the largest market for ophthalmic drugs in the world,
sales reaching $6.5 billion in 2010((1)), and establishing a commercial
here will be a key part of the new business of NicOx."
(1) The Ophthalmic Pharmaceutical Market Outlook to 2016, Business
NOTE: Elestat® is a registered trademark of Boehringer Ingelheim
GmbH and is licensed to Allergan, Inc., AzaSite® is a registered
InSite Vision Inc. and is licensed to Merck and Company and
Restasis® is a
registered trademark of Allergan, Inc.
NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a pharmaceutical company
on the research, development and future commercialization of drug
NicOx is applying its proprietary nitric oxide-donating R&D platform to
an internal portfolio of New Molecular Entities (NMEs) for the
treatment of inflammatory, cardio-metabolic and ophthalmological diseases.
The Company's pipeline includes several nitric oxide-donating NMEs, which
development internally and with partners, who include Merck (known
outside the United States and Canada), Bausch + Lomb and Ferrer.
NicOx S.A. is headquartered in France and is listed on Euronext
(Compartment C: Small Caps).
This press release contains certain forward-looking statements.
Company believes its expectations are based on reasonable assumptions,
forward-looking statements are subject to numerous risks and
which could cause actual results to differ materially from those
the forward-looking statements.
Risks factors which are likely to have a material effect on NicOx's
presented in the 4(th) chapter of the « Document de
référence, rapport financier
annuel et rapport de gestion 2011 » filed with the French
Autorité des Marchés
Financiers (AMF) on February 29, 2012 and available on NicOx's
(www.nicox.com) and on the AMF's website (www.amf-france.org).
Les Taissounières - Bât HB4 - 1681 route des Dolines - BP313 -
Antipolis Cedex - France
Tel: +33 (0)4 97 24 53 00 · Fax: +33 (0)4 97 24 53 99
NicOx:Jerry St. Peter appointed EVP and General:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: NICOX via Thomson Reuters ONE